Payment overview · 2025
General Payments
$14.38
1 reported records · 1 companies
Healthcare provider profile · identity verified
Arpit V Patel, D.O
Allopathic & Osteopathic Physicians|Internal Medicine · TAMPA, FL · NPI 1699047472
Verified facts
What the public records show
CMS Open Payments records show Arpit V Patel, D.O received $14.38 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.38 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 379 | 113 |
| Losartan Potassium | Losartan Potassium | 367 | 101 |
| Lisinopril | Lisinopril | 325 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 95 |
| Omeprazole | Omeprazole | 273 | 80 |
| Celecoxib | Celecoxib | 271 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 73 |
| Prednisone | Prednisone | 213 | 121 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 83 |
| Gabapentin | Gabapentin | 199 | 73 |
| Montelukast Sodium | Montelukast Sodium | 198 | 65 |
| Metformin Hcl | Metformin Hcl | 174 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 49 |
| Furosemide | Furosemide | 152 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 53 |
| Eliquis | Apixaban | 144 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 143 | 96 |
| Doxycycline Hyclate | Doxycycline Hyclate | 119 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 30 |
| Sertraline Hcl | Sertraline Hcl | 105 | 34 |
| Finasteride | Finasteride | 102 | 30 |
| Carvedilol | Carvedilol | 97 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 20 |
| Alprazolam | Alprazolam | 95 | 26 |
| Trazodone Hcl | Trazodone Hcl | 94 | 33 |
| Spironolactone | Spironolactone | 93 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Tramadol Hcl | Tramadol Hcl | 81 | 28 |
| Famotidine | Famotidine | 80 | 30 |
| Simvastatin | Simvastatin | 79 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 24 |
| Metformin Hcl Er | Metformin Hcl | 76 | 24 |
| Methocarbamol | Methocarbamol | 76 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 27 |
| Buspirone Hcl | Buspirone Hcl | 71 | 29 |
| Glipizide | Glipizide | 71 | 22 |
| Ondansetron Odt | Ondansetron | 70 | 26 |
| Azithromycin | Azithromycin | 67 | 58 |
| Allopurinol | Allopurinol | 64 | 20 |
| Mirtazapine | Mirtazapine | 64 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 64 | 17 |
| Alendronate Sodium | Alendronate Sodium | 61 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 17 |
| Baclofen | Baclofen | 57 | 27 |
| Topiramate | Topiramate | 56 | 17 |
| Donepezil Hcl | Donepezil Hcl | 55 | 15 |
| Methylprednisolone | Methylprednisolone | 55 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 13 |
| Atenolol | Atenolol | 50 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 22 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Irbesartan | Irbesartan | 48 | 15 |
| Meloxicam | Meloxicam | 48 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Potassium Chloride | Potassium Chloride | 43 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 18 |
| Meclizine Hcl | Meclizine Hcl | 42 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 17 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | 19 |
| Propranolol Hcl | Propranolol Hcl | 39 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 32 |
| Valsartan | Valsartan | 39 | 12 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 13 |
| Memantine Hcl | Memantine Hcl | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 23 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | 11 |
| Glipizide Er | Glipizide | 31 | 11 |
| Levofloxacin | Levofloxacin | 31 | 21 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 12 |
| Diazepam | Diazepam | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Permethrin | Permethrin | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ivermectin | Ivermectin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.38 · 1 records | Novo Nordisk Inc | Ozempic | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error